Jacobson Pharma Corporation Limited provided earnings guidance for the year ended March 31, 2019. For the year, the company reported that the board of directors of the company announced shareholders of the company and potential investors that, based on a preliminary review on the unaudited consolidated management accounts of the Group for the financial year ended March 31, 2019 and the information currently available to the Board, the Group is expected to record an increase of over 20% in the consolidated profit attributable to shareholders of the Company for the financial year ended March 31, 2019 as compared to that for the financial year ended March 31, 2018. The expected increase is mainly attributable to a steady growth of the Group's generic drug business augmented with the sales revenue generated from newly in-licensed products, in addition to an uplifted sales performance on proprietary medicines. Operating leverage and financial savings derived from cost control measures also helped contribute to the expected increase in earnings. Fair value gain on investment properties of the Group is also expected to contribute, although to a lesser extent, to the increase in consolidated profit attributable to shareholders of the Company.